The University of Manchester led national study of 3,776 patients – treated for early breast cancer at 64 hospitals across the UK – between March and May 2020, is published in The British Journal of Cancer.
The team found that the majority of patients were delivered safe and effective treatment in line with normal practice, on time and to standard, in pre-operative, operative, and post-operative settings.
There were just 14 cases of patients testing positive for COVID-19 in the study, one per cent of the total. None of the patients involved the study died from the disease.
The success, say the team, can be partly explained by the adoption of multidisciplinary UK guidelines, which were published early in the pandemic, advising on the safe management of patients.
In addition, there was rapid adoption of the findings from a 10-year study – known as Fast Forward. Fast Forward was published in May 2020, although guidance arising from it was issued before publication.
Fast Forward recommended shortening radiotherapy course from 15 doses over three weeks to five doses in a week, having showed that five doses was as effective as 15 doses in terms of cancer recurrence.
Though the reduced number of doses are given at a higher intensity, side effects are no different.
Of the 64 hospitals in the study, 46 rapidly introduced the Fast Forward protocol during the period of the study.
Other measures included rigorous COVID-19 testing of patients, operations carried out in COVID-19 free surgical theatres known as ‘green zones’ both in the NHS and private sector, and rapid discharge of patients.
However, some patients did potentially miss out on breast reconstruction surgery which is likely to have implications on the breast service in the future, in terms of needing to offer more reconstructions at a later date.
And though the study only examined existing patients, breast cancer screening has been hit by the pandemic, with reduced numbers of women attending for screening.
However, screening services are now fully open and women can be reassured that safe, COVID-protective measures are in place.
Paper co-author, surgeon Professor Cliona Kirwan, is a Clinician Scientist at The University of Manchester.
She said: “Compromises to cancer care during the COVID-19 pandemic have the potential to impact on survival, as well as quality of life, service provision, and health economics.